Eurofins Scientific Shares Break Below Technical Support at 62.82 Euros
Eurofins Scientific drops 2.73% at midday on Monday, to 62.82 euros, amid a widespread retreat in European stock markets. The stock continues a downward trend that began last week, showing a decline of nearly 7.84% over seven days. This correction occurs as the CAC 40 falls 1.98% during the session and market volatility significantly increases.
Technical Analysis of Eurofins Scientific
The share price of Eurofins Scientific is now trading below its support level at 64.02 euros, which also corresponded to the lower boundary of the Bollinger Bands. This downward breach indicates an acceleration of selling pressure and positions the stock significantly away from its 20-day and 50-day moving averages, which are positioned at 66.46 and 67.60 euros respectively. However, the 200-day moving average, established at 63.10 euros, serves as an immediate proximity reference: a sustained move below this threshold could signal a deeper change in momentum.
The RSI is at 50, a neutral level that indicates neither overbuying nor overselling despite the marked decline in recent days. This reading suggests that the correction has not yet reached an extreme level in terms of price dynamics, leaving open the possibility of a continuation of the movement or stabilization near the 200-day moving average.
Market Context on Monday's Session
Monday's session unfolds in a tense atmosphere across all stock markets. The CAC 40 is down 1.98% during the session, while the DAX drops 1.59% and the FTSE 100 loses 1.42%. In Asia, the Nikkei 225 closed down 5.20%, and the Hang Seng ended 1.35% lower. The VIX, a volatility index measured on the options of the S&P 500, had already jumped 12.29% last Thursday to settle at 23.75 points, reflecting increased nervousness among traders.
In this context, the decline of Eurofins Scientific appears amplified compared to its benchmark index. The stock is down 2.73% versus 1.98% for the CAC 40, even though its historical beta, close to zero (0.09), usually suggests a low sensitivity to market fluctuations. The three-month performance remains positive at 9.14%, as does the one-year performance at 22.31%, which puts the current corrective episode into perspective relative to the medium-term trajectory of the biological analysis services group.
